Literature DB >> 2828792

A comparison of PCP-like compounds for NMDA antagonism in two in vivo models.

D A Bennett1, P S Bernard, C L Amrick.   

Abstract

The PCP-like compounds ketamine and dexoxadrol were evaluated in two behavioral test procedures known to be sensitive to competitive N-methyl-D-aspartate (NMDA) receptor antagonists. In the NMDA-induced convulsion test in mice, ketamine and dexoxadrol blocked convulsant activity only at doses that also induced nonspecific effects of PCP-like behaviors, thereby confounding the interpretation of results. These compounds also blocked NMDA-induced discriminative stimuli in rats; however, this effect was produced at doses lower than those which induced the nonspecific behavioral effects. These results provide evidence that in behavioral procedures, PCP-like compounds may block excitatory amino acid receptor stimulation by NMDA. The NMDA discrimination identifies these interactions without the influence of motor deficit or other behavioral motor effects.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2828792     DOI: 10.1016/0024-3205(88)90083-5

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  10 in total

1.  Genetic differences in the effects of competitive and non-competitive NMDA receptor antagonists on locomotor activity in mice.

Authors:  S Liljequist
Journal:  Psychopharmacology (Berl)       Date:  1991       Impact factor: 4.530

Review 2.  A review of the in vitro and in vivo neurochemical characterization of the NMDA/PCP/glycine/ion channel receptor macrocomplex.

Authors:  P L Wood; T S Rao; S Iyengar; T Lanthorn; J Monahan; A Cordi; E Sun; M Vazquez; N Gray; P Contreras
Journal:  Neurochem Res       Date:  1990-02       Impact factor: 3.996

3.  Nonpsychotropic cannabinoid acts as a functional N-methyl-D-aspartate receptor blocker.

Authors:  J J Feigenbaum; F Bergmann; S A Richmond; R Mechoulam; V Nadler; Y Kloog; M Sokolovsky
Journal:  Proc Natl Acad Sci U S A       Date:  1989-12       Impact factor: 11.205

4.  Dose-dependent effects of repeated ketamine administration on muscarinic acetylcholine receptors in the mouse forebrain.

Authors:  Shinichiro Hitomi; Toshihito Morita; Shigeru Saito; Yoshitaka Uchihashi
Journal:  J Anesth       Date:  1995-09       Impact factor: 2.078

5.  Behavioral studies on FR115427, a novel selective N-methyl-D-aspartate antagonist.

Authors:  H Nakanishi; K Katsuta; Y Ueda; H Takasugi; A Kuno; M Ohkubo; K Ogita; Y Yoneda; K Shirakawa; K Yoshida
Journal:  Psychopharmacology (Berl)       Date:  1995-01       Impact factor: 4.530

6.  Age-dependent differences in sensitivity and sensitization to cannabinoids and 'club drugs' in male adolescent and adult rats.

Authors:  Jenny L Wiley; Rhys L Evans; Darren B Grainger; Katherine L Nicholson
Journal:  Addict Biol       Date:  2007-09-11       Impact factor: 4.280

7.  Ketamine, but not phencyclidine, selectively modulates cerebellar GABA(A) receptors containing alpha6 and delta subunits.

Authors:  Wulf Hevers; Stephen H Hadley; Hartmut Lüddens; Jahanshah Amin
Journal:  J Neurosci       Date:  2008-05-14       Impact factor: 6.167

Review 8.  Phencyclidine. Physiological actions, interactions with excitatory amino acids and endogenous ligands.

Authors:  P C Contreras; J B Monahan; T H Lanthorn; L M Pullan; D A DiMaggio; G E Handelmann; N M Gray; T L O'Donohue
Journal:  Mol Neurobiol       Date:  1987       Impact factor: 5.590

Review 9.  Ketamine: an update on the first twenty-five years of clinical experience.

Authors:  D L Reich; G Silvay
Journal:  Can J Anaesth       Date:  1989-03       Impact factor: 5.063

10.  Antidepressant-relevant concentrations of the ketamine metabolite (2R,6R)-hydroxynorketamine do not block NMDA receptor function.

Authors:  Eric W Lumsden; Timothy A Troppoli; Scott J Myers; Panos Zanos; Yasco Aracava; Jan Kehr; Jacqueline Lovett; Sukhan Kim; Fu-Hua Wang; Staffan Schmidt; Carleigh E Jenne; Peixiong Yuan; Patrick J Morris; Craig J Thomas; Carlos A Zarate; Ruin Moaddel; Stephen F Traynelis; Edna F R Pereira; Scott M Thompson; Edson X Albuquerque; Todd D Gould
Journal:  Proc Natl Acad Sci U S A       Date:  2019-02-22       Impact factor: 11.205

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.